Systolic Heart Failure

Categories: Cardiovascular diseases

Aliases & Classifications for Systolic Heart Failure

MalaCards integrated aliases for Systolic Heart Failure:

Name: Systolic Heart Failure 12 15 17
Heart Failure, Systolic 6 43 71


External Ids:

Disease Ontology 12 DOID:9651
ICD9CM 34 428.2 428.20
MeSH 43 D054143
ICD10 32 I50.20
UMLS 71 C1135191

Summaries for Systolic Heart Failure

MalaCards based summary : Systolic Heart Failure, also known as heart failure, systolic, is related to mitral valve insufficiency and left bundle branch hemiblock. An important gene associated with Systolic Heart Failure is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Myometrial Relaxation and Contraction Pathways. The drugs Carvedilol and Canagliflozin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Systolic Heart Failure

Diseases related to Systolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 487)
# Related Disease Score Top Affiliating Genes
1 mitral valve insufficiency 31.4 NPPB NPPA CRP ACE
2 left bundle branch hemiblock 31.2 NR3C2 NPPB CRP ACE
3 atrial standstill 1 31.1 NPPB NPPA ADRB1 ACE
4 tricuspid valve insufficiency 30.9 NPPB EDN1 CRP ACE
5 congestive heart failure 30.7 TNF NR3C2 NPPB NPPA NOS3 IL6
6 impotence 30.6 NOS3 EDN1 ACE
7 chagas disease 30.6 TNF NPPB IL6 ADRB1 ACE
8 uremia 30.6 TNF IL6 CRP ACE
9 intermediate coronary syndrome 30.5 IL6 CRP ACE
10 myocarditis 30.5 TNF NPPB NPPA IL6 ACE
11 intermittent claudication 30.5 IL6 CRP ACE
12 rheumatic heart disease 30.5 TNF NPPB IL6 ACE
13 sexual disorder 30.4 NOS3 EDN1 ADRB1 ACE
14 acute myocarditis 30.4 NPPB IL6 CRP ACE
15 decubitus ulcer 30.3 TNF MMP9 IL6 CRP
16 pericardial effusion 30.3 NPPB NPPA IL6 CRP ACE
17 lipid metabolism disorder 30.3 IL6 CRP ADIPOQ ACE
18 gastroenteritis 30.3 TNF MMP9 IL6 CRP
19 peripheral vascular disease 30.2 TIMP1 NOS3 IL6 CRP ACE
20 diastolic heart failure 30.2 NPPB NPPA NOS3 MMP9 MMP2 CST3
21 central sleep apnea 30.1 NPPB NPPA NOS3 HSPB7 CRP ACE
22 connective tissue disease 30.1 TNF IL6 EDN1 CRP ACE
23 leptin deficiency or dysfunction 30.1 TNF IL6 CRP ADIPOQ
24 anxiety 30.0 UCN TNF IL6 CRP
25 sleep apnea 30.0 TNF NPPB NOS3 IL6 EDN1 CRP
26 hypothyroidism 30.0 TNF CST3 CRP ADIPOQ ACE
27 pheochromocytoma 30.0 TNF NPPA IL6 EDN1 ACE
28 amyloidosis 30.0 TNF NPPB IL6 CST3 CRP
29 coronary stenosis 30.0 NPPB IL6 CRP ADIPOQ ACE
30 sleep disorder 30.0 TNF IL6 EDN1 CRP ADIPOQ ACE
31 angina pectoris 29.9 NPPB NOS3 IL6 EDN1 CRP ADRB1
32 mitral valve disease 29.9 NPPB NPPA NOS3 CRP ACE
33 atrial fibrillation 29.9 NR3C2 NPPB NPPA NOS3 LGALS3 IL6
34 aortic valve disease 2 29.9 NPPB NPPA NOS3 CRP ACE
35 hypertensive heart disease 29.8 NR3C2 NPPB NPPA MMP9 MMP2 ACE
36 heart valve disease 29.8 NR3C2 NPPB NPPA EDN1 CRP ACE
37 lung disease 29.8 TNF NPPB MMP9 IL6 EDN1 CRP
38 pulmonary disease, chronic obstructive 29.7 TNF TIMP1 NPPB MMP9 IL6 CRP
39 arteries, anomalies of 29.7 TNF NPPB NOS3 MMP9 IL6 EDN1
40 coronary heart disease 1 29.6 NPPB NOS3 IL6 EDN1 CRP ADIPOQ
41 coronary artery anomaly 29.6 TNF NPPB NPPA NOS3 MMP9 IL6
42 pulmonary hypertension 29.6 TNF TIMP1 NPPB NPPA NOS3 IL6
43 pulmonary edema 29.5 TNF NR3C2 NPPB NPPA NOS3 EDN1
44 deficiency anemia 29.5 TNF TIMP1 NPPA IL6 CST3 CRP
45 apnea, obstructive sleep 29.4 TNF NOS3 IL6 EDN1 CRP ADIPOQ
46 end stage renal failure 29.4 TNF NPPB NPPA IL6 CST3 CRP
47 heart disease 29.4 TNF NR3C2 NPPB NPPA NOS3 MMP9
48 cerebrovascular disease 29.2 TNF NPPB NPPA MMP9 IL6 CRP
49 respiratory failure 29.2 TNF TIMP1 NPPB NPPA IL6 EDN1
50 acute myocardial infarction 29.1 NR3C2 NPPB NPPA MMP9 IL6 EDN1

Graphical network of the top 20 diseases related to Systolic Heart Failure:

Diseases related to Systolic Heart Failure

Symptoms & Phenotypes for Systolic Heart Failure

MGI Mouse Phenotypes related to Systolic Heart Failure:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 ACE ADIPOQ ADRB1 CORIN CRP CST3
2 homeostasis/metabolism MP:0005376 10.41 ACE ADIPOQ ADRB1 CORIN CRP CST3
3 growth/size/body region MP:0005378 10.32 ACE ADIPOQ ADRB1 CORIN EDN1 HSPB7
4 mortality/aging MP:0010768 10.25 ACE ADIPOQ ADRB1 CST3 EDN1 HSPB7
5 muscle MP:0005369 10.21 ADIPOQ ADRB1 CORIN CST3 EDN1 GRK5
6 hematopoietic system MP:0005397 10.2 ACE ADIPOQ IL6 LGALS3 MMP2 MMP9
7 endocrine/exocrine gland MP:0005379 10.19 ACE ADIPOQ ADRB1 CST3 EDN1 GRK5
8 adipose tissue MP:0005375 10.07 ACE ADIPOQ ADRB1 IL6 LGALS3 NOS3
9 nervous system MP:0003631 10.03 ADIPOQ CST3 EDN1 GRK5 IL6 LGALS3
10 neoplasm MP:0002006 9.97 ACE ADIPOQ CST3 IL6 LGALS3 MMP2
11 renal/urinary system MP:0005367 9.85 ACE ADIPOQ CORIN EDN1 IL6 LGALS3
12 respiratory system MP:0005388 9.65 ADIPOQ GRK5 HSPB7 IL6 LGALS3 MMP2
13 skeleton MP:0005390 9.32 ADIPOQ ADRB1 EDN1 IL6 LGALS3 MMP2

Drugs & Therapeutics for Systolic Heart Failure

Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
Canagliflozin Approved Phase 4 842133-18-0
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
Bisoprolol Approved Phase 4 66722-44-9 2405
Sodium citrate Approved, Investigational Phase 4 68-04-2
Atorvastatin Approved Phase 4 134523-00-5 60823
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
Enalaprilat Approved Phase 4 76420-72-9 6917719
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
Metformin Approved Phase 4 657-24-9 14219 4091
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
Eplerenone Approved Phase 4 107724-20-9 150310 443872
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
Simendan Investigational Phase 4 131741-08-7
21 Adrenergic alpha-Antagonists Phase 4
22 Incretins Phase 4
23 Dipeptidyl-Peptidase IV Inhibitors Phase 4
24 Sitagliptin Phosphate Phase 4
25 Sodium-Glucose Transporter 2 Inhibitors Phase 4
26 Phosphodiesterase 5 Inhibitors Phase 4
27 Phosphodiesterase Inhibitors Phase 4
28 Anti-Arrhythmia Agents Phase 4
29 Adrenergic beta-1 Receptor Antagonists Phase 4
30 Sympatholytics Phase 4
31 Natriuretic Peptide, Brain Phase 4
32 Platelet Aggregation Inhibitors Phase 4
33 Prasugrel hydrochloride Phase 4 389574-19-0
34 Purinergic P2Y Receptor Antagonists Phase 4
35 Citrate Phase 4
36 Sildenafil Citrate Phase 4 171599-83-0
37 Anticholesteremic Agents Phase 4
38 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
39 Thiamin Phase 4
40 Adrenergic beta-Antagonists Phase 4
41 Adrenergic Antagonists Phase 4
42 Angiotensin II Type 1 Receptor Blockers Phase 4
43 Giapreza Phase 4
44 Angiotensinogen Phase 4
45 Phosphodiesterase 3 Inhibitors Phase 4
46 Angiotensin Receptor Antagonists Phase 4
47 LCZ 696 Phase 4
48 Hormone Antagonists Phase 4
49 Mineralocorticoids Phase 4
50 Mineralocorticoid Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 233)
# Name Status NCT ID Phase Drugs
1 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
2 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
3 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
4 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
5 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
6 A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure Completed NCT02920918 Phase 4 Canagliflozin;Sitagliptin
7 Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure Completed NCT01765400 Phase 4 Prasugrel 10 mg daily x 2 weeks;Clopidogrel 75 mg daily x 2 weeks
8 SASHFR (South Asian Systolic Heart Failure Registry) : A Multi-center, Nonrandomized, Prospective Study to Collect Data Pertaining to the Demographic and Cardiovascular Profiles, Management Strategies and Clinical Outcomes of HF Patients. Completed NCT01434615 Phase 4
9 Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial Completed NCT02401126 Phase 4
10 Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
11 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
12 A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis Completed NCT00795912 Phase 4 Atorvastatin
13 Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97 mg Sacubitril / 103 mg Valsartan Bid in Patients With HFrEF Completed NCT02690974 Phase 4 LCZ696 (sacubitril/valsartan)
14 A Randomized Controlled Trial of the Effect of Thiamin Supplementation on Heart Function in Ambulatory Patients With Heart Failure Completed NCT00959075 Phase 4
15 Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
16 A Randomized, Double-blind, Placebo-controlled Study of the Effect of Mineralocorticoid Receptor Antagonists in Type 2 Diabetes Patients on Myocardial Function, Glucose and Fat Metabolism (The MIRAD-study) Completed NCT02809963 Phase 4 Eplerenone;Placebo
17 SIDAMI - Sildenafil and Diastolic Dysfunction After AMI Completed NCT01046838 Phase 4 Sildenafil;Placebo
18 Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality - FAIR-HF2 Recruiting NCT03036462 Phase 4 Iron;Saline
19 Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton Recruiting NCT03553303 Phase 4 Sacubitril / Valsartan Oral Tablet
20 Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations Recruiting NCT03764722 Phase 4 Levosimendan
21 Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial Recruiting NCT03096613 Phase 4 Levothyroxine
22 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
23 A Randomized, Double-blind, Active-controlled Study to Assess the Effect of LCZ696 Compared With Enalapril to Improve Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF). Active, not recruiting NCT02768298 Phase 4 LCZ696;enalapril;Enalapril matching placebo;LCZ696 matching placebo
24 Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins Active, not recruiting NCT02797340 Phase 4 Metformin
25 Cluster and Registry Trials Of the Working Group of Heart Failure in Denmark: Are SPironolactone and Eplerenone Comparable Treatments? Not yet recruiting NCT03984591 Phase 4 Eplerenone;Spironolactone
26 The Effect of Ferric Carboximaltose on Intra-myocardial Iron Load Assessed by Cardiac Magnetic Resonance in Patients With Heart Failure With Reduced Ejection Fraction (HFREF). Not yet recruiting NCT03871699 Phase 4 Ferric carboxymaltose
27 Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study. Not yet recruiting NCT03392740 Phase 4 Lisinopril;Placebo Oral Tablet
28 Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability Not yet recruiting NCT03890939 Phase 4
29 Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output: A Single Center, Randomized, Non-Blinded, and Parallel Study (PRIORITY-ADHF Study) Withdrawn NCT02767024 Phase 4 Sodium nitroprusside;Dobutamine;Furosemide
30 Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets (FIRST) Unknown status NCT02188082 Phase 2, Phase 3 IvabRadine hemisulfate Sustained-release Tablets;placebo
31 Impact of Renal Artery Denervation in Patients With Chronic Heart Failure Compared With Sham Procedure Unknown status NCT01639378 Phase 3
32 MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy Unknown status NCT01640769 Phase 3
33 Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure Unknown status NCT01913847 Phase 3 Sildenafil;Placebo
34 Intracoronary Infusion of BM-Derived Mononuclear Cells in Patients With Large Acute Myocardial Infarction Unknown status NCT00497211 Phase 2, Phase 3
35 The Effect of Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia Completed NCT02998697 Phase 2, Phase 3 Ferrous Sulfate;Placebo Oral Capsule
36 Spinal Cord Stimulation For Heart Failure As A Restorative Treatment Completed NCT01362725 Phase 2, Phase 3
37 Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure Completed NCT00206310 Phase 3 CRESTOR
38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
39 A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of the Celacade™ System on Mortality and Morbidity in Patients With Chronic Heart Failure Completed NCT00111969 Phase 3
40 The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure Completed NCT00232180 Phase 3 Eplerenone
41 Thiamine Supplementation in Heart Failure Patients Receiving Full Medical Therapy Completed NCT01115504 Phase 3 Thiamine
42 Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension Completed NCT00820352 Phase 3 bosentan;placebo
43 Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic Completed NCT00523757 Phase 3 Spironolactone;Placebo
44 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease Completed NCT01754259 Phase 3 Ranolazine;Placebo
45 A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction Recruiting NCT03917459 Phase 3 LCZ696;Enalapril matching placebo;Enalapril;LCZ696 matching placebo
46 Cardiovascular Effects of Preferred Home-based Exercise Training and Extended Adherence Measures in Systolic Heart Failure - Pilot Study Recruiting NCT02051712 Phase 3
47 Investigator-initiated, Randomized, Double-blind, Controlled, Multi-center Trial of Intrvenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency Recruiting NCT03991000 Phase 3 Ferric carboxymaltose;Saline
49 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients Recruiting NCT03662789 Phase 2, Phase 3 Iron Isomaltoside 1000
50 Sildenafil in US Heart Failure Patients (SilHF-US) Recruiting NCT03460470 Phase 3 Sildenafil;Placebo oral capsule

Search NIH Clinical Center for Systolic Heart Failure

Cochrane evidence based reviews: heart failure, systolic

Genetic Tests for Systolic Heart Failure

Anatomical Context for Systolic Heart Failure

MalaCards organs/tissues related to Systolic Heart Failure:

Heart, Kidney, Testes, Brain, Endothelial, Bone, Lung

Publications for Systolic Heart Failure

Articles related to Systolic Heart Failure:

(show top 50) (show all 2293)
# Title Authors PMID Year
Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. 61
31584516 2020
Targeted and Controlled Drug Delivery to a Rat Model of Heart Failure Through a Magnetic Nanocomposite. 61
31696331 2020
Endothelial dysfunction and glycocalyx shedding in heart failure: insights from patients receiving cardiac resynchronisation therapy. 61
31455993 2020
Contemporary personalized β-blocker management in the perioperative setting. 61
31637510 2020
Diagnostic and prognostic value of autoantibodies against β1-adrenoreceptors in patients with heart failure following acute myocardial infarction: A 5-year prospective study. 61
32010297 2020
The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure: Author's reply. 61
32031228 2020
MicroRNA-183-3p up-regulated by vagus nerve stimulation mitigates chronic systolic heart failure via the reduction of BNIP3L-mediated autophagy. 61
31629817 2020
Does sympathetic hyperactivity adversely impact on the effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure? 61
32031229 2020
Synergistic prognostication of left ventricular hypertrophy and three-dimensional mechanical dyssynchrony in heart failure. 61
31965750 2020
Iron Deficiency Is Associated with Adverse Outcomes in Pediatric Heart Failure. 61
31610927 2020
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction. 61
31838035 2020
Sleep duration and architecture during ASV for central sleep apnoea in systolic heart failure. 61
31526873 2020
The interactions between respiratory and cardiovascular systems in systolic heart failure. 61
31774354 2020
Peripartum Cardiomyopathy: JACC State-of-the-Art Review. 61
31948651 2020
Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). 61
31711634 2020
Registry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL): Rationale, design, baseline characteristics, and inclusion criteria performance. 61
31679943 2020
The infarction zone rather than the noninfarcted remodeling zone overexpresses angiotensin II receptor type 1 and is the main source of ventricular atrial natriuretic peptide. 61
31759320 2020
Prevention and rescue of cardiac dysfunction by methanocarba adenosine monophosphonate derivatives. 61
31989534 2020
Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. 61
31822442 2020
Frequency and Predictors of Polypharmacy in US Medicare Patients: A Cross-Sectional Analysis at the Patient and Physician Levels. 61
31782129 2020
Baseline Right Ventricular Dysfunction Predicts Worse Outcomes in Patients Undergoing Cardiac Resynchronization Therapy (CRT) Implantation. 61
31881279 2019
Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI. 61
31955812 2019
Unusual Presentation of Acute Systolic Heart Failure Caused by Acquired Post-Traumatic Aortic Coarctation. 61
31805781 2019
Ventricular fibrillation associated with Graves' disease and amiodarone induced thyrotoxicosis. 61
31942554 2019
Effect of Treatment of Central Sleep Apnea/Cheyne-Stokes Respiration on Left Ventricular Ejection Fraction in Heart Failure: A Network Meta-Analysis. 61
31855167 2019
123I-MIBG cardiac sympathetic imaging provides further insight into cardiorenal interactions in systolic heart failure patients. 61
31875284 2019
The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. 61
31691436 2019
Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF. 61
31779926 2019
Direct Sarcomere Modulators Are Promising New Treatments for Cardiomyopathies. 61
31905684 2019
Examination of attention, executive function, and memory as predictors of mortality risk in adults with systolic heart failure. 61
31342781 2019
Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. 61
31591826 2019
Association between Type D personality and outcomes in patients with non-ischemic heart failure. 61
31292822 2019
Predictors of one-year outcomes in chronic heart failure: the portrait of a middle income country. 61
31706288 2019
Range Variability in CMR Feature Tracking Multilayer Strain across Different Stages of Heart Failure. 61
31712641 2019
Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure. 61
31356682 2019
Salivary Protein Panel to Diagnose Systolic Heart Failure. 61
31766659 2019
Systolic Heart Failure: An Update for Home Healthcare Clinicians. 61
31688465 2019
Systolic Heart Failure: An Update for Home Healthcare Clinicians. 61
31688480 2019
Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. 61
31757654 2019
Baseline and Exercise Predictors of VO2peak in Systolic Heart Failure Patients: Results from SMARTEX-HF. 61
31688648 2019
Predictors of Survival for Patients with Acute Decompensated Heart Failure Requiring Extra-Corporeal Membrane Oxygenation Therapy. 61
30312208 2019
Development and Validation of a Prediction Model for Atrial Fibrillation Using Electronic Health Records. 61
31753441 2019
Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy. 61
31768884 2019
Systolic aortic root motion predicts response to cardiac resynchronization therapy. 61
31453634 2019
Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs. 61
31751570 2019
Left ventricular function after correction of mitral regurgitation: Impact of the clipping approach. 61
31682044 2019
[MITRA-FR and COAPT : Why are the results so different and what are the consequences for the daily routine?] 61
31428798 2019
Successful Combined Heart and Kidney Transplantation in Patient With Fabry's Disease: A Case Report. 61
31371217 2019
Diastolic dysfunction is associated with an increased risk of postcontrast acute kidney injury. 61
31770210 2019
[Why not integrate the spectral tissue Doppler E/(e'xs') in the multiparametric assessment of cardiovascular diseases by transthoracic Doppler echocardiography?] 61
31466722 2019

Variations for Systolic Heart Failure

ClinVar genetic disease variations for Systolic Heart Failure:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ANKRD1 NM_014391.2(ANKRD1):c.827C>T (p.Ala276Val)SNV Conflicting interpretations of pathogenicity 45639 rs35550482 10:92675322-92675322 10:90915565-90915565
2 TTN NM_001267550.2(TTN):c.5668C>T (p.Arg1890Cys)SNV Conflicting interpretations of pathogenicity 47210 rs146496197 2:179640923-179640923 2:178776196-178776196
3 DSG2 NM_001943.5(DSG2):c.1543G>A (p.Val515Ile)SNV Benign/Likely benign 36010 rs2230235 18:29116284-29116284 18:31536321-31536321
4 DSP NM_004415.4(DSP):c.8300C>A (p.Thr2767Asn)SNV Benign/Likely benign 44963 rs34884895 6:7585795-7585795 6:7585562-7585562
5 DTNA NM_001390.4(DTNA):c.1357C>A (p.Pro453Thr)SNV Benign 46411 rs77320474 18:32431798-32431798 18:34851834-34851834

Expression for Systolic Heart Failure

Search GEO for disease gene expression data for Systolic Heart Failure.

Pathways for Systolic Heart Failure

Pathways related to Systolic Heart Failure according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
5 12.07 TNF MMP9 MMP2 IL6 GRK5
Show member pathways
12.02 TNF MMP9 MMP2 IL6
7 11.99 TNF MMP9 LGALS3 IL6
8 11.97 TNF NOS3 MMP9 MMP2 EDN1
9 11.93 TNF MMP9 IL6 EDN1
Show member pathways
11 11.82 TNF TIMP1 MMP9 MMP2 IL6
12 11.8 TIMP1 NOS3 MMP9 MMP2
13 11.76 TIMP1 NPPA NOS3 IL6 EDN1
Show member pathways
11.74 NR3C2 NOS3 ACE
15 11.69 TNF MMP9 IL6
16 11.65 NPPA EDN1 ADRB1 ACE
17 11.64 MMP9 MMP2 IL6
18 11.62 NOS3 MMP9 MMP2 LGALS3
19 11.61 TIMP1 MMP9 MMP2
Show member pathways
11.58 TNF MMP9 MMP2 IL6
21 11.55 TNF NOS3 MMP2 IL6 EDN1
22 11.53 TNF MMP2 IL6
23 11.51 TNF TIMP1 IL6
24 11.39 TNF MMP9 MMP2 IL6
25 11.37 TNF NPPA IL6
26 11.32 NOS3 EDN1 ADRB1
27 11.28 MMP9 MMP2 ACE
Show member pathways
11.24 TIMP1 EDN1 CRP
29 11.17 NOS3 MMP9 MMP2
30 11.09 NOS3 MMP9 MMP2 IL6
31 11.08 TNF IL6 ADIPOQ
32 10.99 TNF IL6 CRP
33 10.9 TNF TIMP1 MMP9 MMP2 IL6 EDN1
34 10.62 MMP9 MMP2 CST3 ACE

GO Terms for Systolic Heart Failure

Cellular components related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 TNF TIMP1 NPPB NPPA MMP9 MMP2
2 collagen-containing extracellular matrix GO:0062023 9.55 NPPA MMP9 MMP2 LGALS3 ADIPOQ
3 extracellular region GO:0005576 9.5 UCN TNF TIMP1 NPPB NPPA MMP9

Biological processes related to Systolic Heart Failure according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 UCN TNF NOS3 IL6 CRP
2 cytokine-mediated signaling pathway GO:0019221 9.88 TNF TIMP1 MMP9 MMP2 IL6
3 positive regulation of protein phosphorylation GO:0001934 9.85 UCN TNF MMP9 ADIPOQ
4 response to hypoxia GO:0001666 9.83 NPPA MMP2 EDN1 ADIPOQ
5 cellular protein metabolic process GO:0044267 9.83 TIMP1 NPPA MMP2 IL6 CST3
6 extracellular matrix disassembly GO:0022617 9.75 TIMP1 MMP9 MMP2
7 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.74 TNF NR3C2 EDN1
8 positive regulation of interleukin-6 production GO:0032755 9.73 UCN TNF IL6
9 negative regulation of fat cell differentiation GO:0045599 9.69 TNF IL6 ADIPOQ
10 response to glucocorticoid GO:0051384 9.67 UCN TNF IL6 ADIPOQ
11 negative regulation of blood pressure GO:0045776 9.63 UCN NOS3 ADIPOQ
12 positive regulation of cardiac muscle contraction GO:0060452 9.62 UCN NPPA
13 cGMP biosynthetic process GO:0006182 9.62 NPPB NPPA
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.62 TNF MMP2 IL6 EDN1
15 regulation of neuroinflammatory response GO:0150077 9.61 MMP9 IL6
16 receptor guanylyl cyclase signaling pathway GO:0007168 9.61 NPPB NPPA
17 body fluid secretion GO:0007589 9.6 NPPB EDN1
18 neutrophil mediated immunity GO:0002446 9.58 IL6 ACE
19 regulation of blood vessel diameter GO:0097746 9.58 NPPB NOS3 ACE
20 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.54 NOS3 EDN1
21 positive regulation of mononuclear cell migration GO:0071677 9.49 TNF LGALS3
22 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 TNF MMP9 MMP2 EDN1
23 negative regulation of hormone secretion GO:0046888 9.43 UCN EDN1 ADIPOQ
24 negative regulation of lipid storage GO:0010888 9.13 TNF IL6 CRP
25 regulation of blood pressure GO:0008217 9.1 NPPB NPPA NOS3 EDN1 CORIN ACE

Molecular functions related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 UCN TNF TIMP1 NR3C2 NPPB NPPA
2 cytokine activity GO:0005125 9.35 TNF TIMP1 IL6 EDN1 ADIPOQ
3 hormone receptor binding GO:0051427 9.26 NPPB NPPA
4 hormone activity GO:0005179 9.02 UCN NPPB NPPA EDN1 ADIPOQ

Sources for Systolic Heart Failure

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....